Pitavastatin: Nissan/Kowa Yakuhin/Novartis/Sankyo

Current Opinion in Investigational Drugs

Volumn 3, Issue 9, 2002, Pages 1334-1341

  Flores, Nicholas A ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ITABASTATIN; KN 104; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NK 105; P 872441; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; QUINOLINES;

EID: 0036771439     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. 174977 Pharmacological studies on NK-104, a novel potent HMG-CoA reductase inhibitor (1): Inhibitory effects on the enzyme (in vitro) and sterol synthesis (in vivo) in rats and hypolipidemic effects in dogs. Nakagawa S, Aoki T, Suzuki H, Tamaki T, Wada Y, Yokoo N, Kitahara M, Saito Y Jpn J Pharmacol 1995 67 Suppl 1 1-53
2. 174978 Pharmacological studies on NK-104, a novel potent HMG-CoA reductase inhibitor (2): Plasma lipid-lowering effects in guinea pigs. Aoki T, Nakagawa S, Suzuki H, Tamaki T, Wada Y, Yokoo N, Kitahara M, Saito Y Jpn J Pharmacol 1995 67 Suppl 1 285 Plasma lipid-lowering effects of NK-104 reported in guinea pigs. Increased potency compared do simvastatin was also noted.
3. 176066 A novel synthetic method of HMG-CoA reductase inhibitor NK-104 via a hydroboration-cross coupling sequence. Tetrahedron Lett 1993 34 51 8267-8270
4. 176068 A new synthesis of HMG-CoA reductase inhibitor NK-104 through hydrosilylation-cross coupling reaction. Takahashi K, Minami T, Ohara Y, Hiyama T Tetrahedron Lett 1993 34 51 8263-8266
5. 176070 A novel enantioselective synthesis of HMG Co-A reductase inhibitor NK-104 and a related compound. Tetrahedron Lett 1992 33 49 7525-7526
6. 192466 Studies on the mechanism of cholesterol- and triglyceride-lowering action of NK-104 in guinea pigs. Tamaki T, Aoki T, Nakagawa S, Suzuki H, Wada Y, Yokoo N, Kitahara M, Saito Y Int Symp on Drugs Affect Lipid Metab 1995 12 64
7. 192485 Inhibition of HMG-COA reductase by NK-104 suppresses intimal thickening via inhibiting smooth muscle cell growth and matrix formation in balloon injured rabbit artery. Kitahara M, Kanaki T, Tanaka S, Tamaki T, Saito Y Int Symp on Drugs Affect Lipid Metab 1995 12 128
8. 192496 NK-104: Efficacy and tolerance of a new synthetic HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. Nakaya N, Kojima J, Kimata H, Kuwahata R, Narusima H Int Symp On Drugs Affect Lipid Metab 1995 12 137 Double-blind placebo-controlled clinical trial of nisvastatin in 35 hypercholesterolemic volunteers. Good tolerance, cholesterol and triglyceride-lowering and HDL increase were shown.
9. 195752 Synthesis of an artificial HMG-CoA reductase inhibitor NK-104 via a hydrosilylation-cross-coupling reaction. Takahashi K, Minami T, Ohara Y, Hiyama T Bull Chem Soc Jpn 1995 68 9 2649-2656
10. 289752 LDL-receptor enhancing effect of NK-104 (nisvastatin) in HEPG2 cells (in vivo) and in guinea pigs (in vivo). Aoki T, Nakagawa S, Tamaki T, Sato F, Kitahara M, Saito Y Int Symp On Drugs Affect Lipid Metab 1998 13 47
11. 289799 NK-104 (nisvastatin) suppresses foam cell formation induced by denatured low density lipoprotein in J774 macrophages. Kitahara M, Kanaki T, Tamaki T, Tanaka S, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 49
12. 289860 Lipid-lowering antiatherosclerotic effect of NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, in WHHL rabbits. Suzuki H, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 53
13. 289877 Inhibitory effect on NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, on VLDL secretion in guinea pigs. Liver perfusion studies after 2-week dosage. Suzuki H, Tamaki T, Aoki T, Sato F, Kitahara M, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 54
14. 292693 Efficacy of NK-104 (nisvastatin), a new totally synthetic HMG-CoA reductase inhibitor, in heterozygous familial hypercholesterolemia. Kajinami K, Koizumi J, Miyamoto S, Takegoshi T, Mabuchi H et al Int Symp on Drugs Affect Lipid Metab 1998 13 63
15. 292695 Pharmacokinetics of NK-104 (nisvastatin) in animals and humans. Kimata H, Kojima J, Fujino H, Koide T, Yamada Y, Yoshimura M, Nakabeppu H, Nakaya N, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 63
16. 292778 NK-104 (nisvastatin) suppresses arterial neointimal thickening by endothelial injury in rabbits via inhibiting smooth muscle cell growth and fibronectin production. Kitahara M, Kanaki T, Miyakoshi C, Kamon J, Tamaki T, Tanaka S, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 95
17. 292788 Antithrombotic effects of E-5510 in experimental thrombosis models. Fujimori T, Saeki T, Harada K, Sato M, Ohshima N Thromb Haemost 1987 58 1 172
18. 292985 NK-104 (nisvastatin): Comparative study on the time course of mRNA induction for LDL receptor and HMG-CoA reductase in Hep G2 cells by HMG-CoA reductase inhibitors. Umetani M, Morikawa S, Kodama T, Saito Y Int Symp on Drugs Affect Lipid Metab 1998 13 128
19. 293020 Clinical effect of NK-104 (nisvastatin) on hyperlipidemia - Double-blind comparative dose-finding study in three parallel groups. Yamada N, Goto Y, Saito Y et al Int Symp on Drugs Affect Lipid Metab 1998 13 129
20. 309368 NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Kitahara M, Kanaki T, Toyoda K, Miyakoshi C, Tanaka S, Tamaki T, Saito Y Jpn J Pharmacol 1998 77 2 117-128
21. 317634 Antigenicity studies of (+)-monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hept enoate] (NK-104) in guinea pigs. Ichinohe H, Yoshimura H, Amano Y, Tanaka M, Takimoto M Pharmacokinetics 1998 56 3-4 179-182
22. 317635 Reproductive and developmental toxicity studies of (+)-monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hept enoate] (NK-104): 4. Perinatal and postnatal study in rats by oral administration. Nishigaki K, Moriwaki T, Akiba T, Okamura N, Koga T, Tanaka M, Takimoto M Pharmacokinetics 56 3-4 161-177
23. 317636 Reproductive and developmental toxicity study of (+)-monocalcium bis (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hepte noate] (NK-104): 3. Teratogenicity study in rabbits by oral administration. Nishigaki K, Moriwaki T, Akiba T, Yamada H, Okamura N, Koga T, Tanaka M, Takimoto M Pharmacokinetics 1998 56 3-4 153-159
24. 317637 Reproductive and developmental toxicity studies of (+)-monocalcium bis (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hepte noate] (NK-104): 2. Teratogenicity study in rats by oral administration. Nishigaki K, Moriwaki T, Akiba T, Yamada H, Okamura N, Watanabe T, Koga T, Tanaka M, Takimoto M Pharmacokinetics 1998 56 3-4 139-152
25. 317639 Reproductive and developmental toxicity studies of (+)-monocalcium bis [3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hepte noate] (NK-104): 1. Fertility study in rats by oral administration. Kamijima M, Hirasawa S, Sekitani T, Kinoshita K, Nishigaki T, Takimoto M Pharmacokinetics 1998 56 3-4 131-138
26. 317640 A 12-month oral toxicity study of (+)-monocalcium bis [(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (NK-104) in dogs followed by a 2-month recovery test. Shibuta T, Kato Y, Amano Y, Kakishita T, Tanaka M, Takimoto M Pharmacometrics 1998 56 3-4 101-130
27. 317641 A 3-month oral toxicity study of (+)-monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hept enoate] (NK-104) in dogs followed by a 7-week recovery test. Shibuta T, Kato Y, Kakishita T, Tanaka M, Takimoto M Pharmacometrics 1998 56 3-4 73-99
28. 317643 Single dose toxicity studies of (+)-monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hept enoate] (NK-104) in rats and dogs. Shibuta T, Kato Y, Akiba T, Ohkuba M, Kakishita T, Tanaka M, Takimoto M Pharmacometrics 1998 56 3-4 67-72
29. 317644 Six-month repeated oral toxicity study of NK-104 in rats. Akita T, Shibuta T, Amano Y, Asanuma A, Okubo M, Nishigaki K, Moriwaki T, Yamada H, Okamura N, Watanabe T, Koga T, Tanaka M J Toxicol Sci 1998 23 Suppl 5 713-720
30. 317645 28-Day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats. Akiba T, Shibuta T, Amano Y, Okubo M, Asanuma A, Koga T, Tanaka M, Takimoto M J Toxicol Sci 1998 23 Suppl 5 701-711
31. 323384 Current pharmaceutical topic and blockbusters from Japan (Part II). Nakamura K Pharma Jpn 1999 645 9
32. 327068 Sankyo to comarket itavastatin with Kowa. Pharma Jpn 1999 1649 3
33. 351665 Kowa, Nissan Chemical file NDA for itavastatin. Pharma Jpn 1999 1677 3
34. 351753 Drug development pipeline: NK-104. Nissan Chemical Industries Ltd Company Communication 2000 January 06
35. 359273 First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104. Suzuki M, Yanagawa Y, Iwasaki H, Kanda H, Yanagihara K, Matsumoto H, Ohara Y, Yazaki Y, Sakoda R Bioorg Med Chem Lett 1999 8 20 2977-2982
36. 359276 Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Yamamoto K, Todaka N, Goto H, Jayaooriya AP, Sakono M, Ogawa Y, Fukuda N Life Sci 1999 65 1493-1502 NK-104 exerts its hypotriglyceridemic action by diverting exogenous free fatty acid to oxidative pathways.
37. 359278 NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Yanagita T, Hara E, Yotsumoto H, Rahman SM, Han SY, Cha JY, Yamamoto K Curr Ther Res Clin Exp 1999 60 423-434
38. 359281 Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor in guinea pigs. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y Atherosclerosis 1999 146 259
39. 359285 Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor in rat, rabbit, and dog bile. Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, Kimata H Biol Pharm Bull 1999 22 2 142-150
40. 359287 NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from HepG2 cells. Ooyen C, Zecca A, Bersino AM, Catapano AL Atherosclerosis 1999 145 1 87-95 The ability of NK-104 to decrease apolipoprotein B-100 secretion is due to decreased intracellular cholesterol availability.
41. 359291 Mutagenicity studies of (+)-monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hept anoate] (NK-104). Okamura N, Moriwaki T, Yamada H, Koga T, Tanaka M, Oguma Y, Yokota F, Nakajima M, Takimoto M Pharmacometrics 1999 57 1-12
42. 359297 Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H, The Hokuriku NK 104 Study group Am J Cardiol 2000 85 2 178-183
43. 359299 Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variations in laboratory animals and humans. Fujino H, Kojima J, Yamada Y, Kanda H, Kimata H Xenobiot Metab Dispos 1999 14 79-91 NK-104 was hardly metabolized via the cytochrome P450-mediated pathway in humans.
44. 368212 Pharmaceutical division. Nissan Chemical Industries Ltd Company World Wide Web Site 2000 May 25
45. 369870 Influences of itavastatin a new HMG-CoA reductase inhibitor on glucose metabolism and LDL size in patients with hyperlipidemia and NIDDM. Yomada N, Saito Y, Akanuma Y Diabetes 2000 49 Suppl 1 Abs 1783-P
46. 373118 Sankyo aims at 50% of overseas sales via independent marketing. Pharma Jpn 2000 1701 June 19 15-17
47. 373239 XII International Symposium on Atherosclerosis, Stockholm, Sweden. Elisaf M IDDB Meeting Report 2000 June 25-29
48. 380313 Kowa, Nissan Chemical, Sankyo agree on development, marketing of itavastatin. Pharma Jpn 2000 1709 3
49. 383887 A new HMG-CoA reductase inhibitor, NK-104: QSAR studies. Mutsukado M, Suzuki M Int Symp Med Chem 2000 16 September 18-22 PA143
50. 397612 Sankyo completes purchase of Sankyo Parke Davis stocks from Pfizer. Pharma Jpn 2001 1731 January 29
51. 398715 SkyePharma selected by Kowa as partner for development of their new statin NK-104. SkyePharma Plc Press Release 2001 February 12
52. 400514 Drugs under development in Japanese companies. Pharma Jpn 2001 1735 9-13
53. 407044 Novartis acquires European rights to 'super-statin' cholesterol treatment pitavastatin. Novartis AG Press Release 2001 April 23
54. 407281 NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Takemoto M, Kitahara M, Yokote K, Asamumi S, Take A, Saito Y, Mori S Br J Pharmacol 2001 133 1 83-88
55. 412603 Novartis bids on "superstatin": Seeking US rights to pivastatin. FDC Reports Pink Sheet 2001 63 24 9
56. 415750 To gain a greater shar in the US first: Mr Shoda of Sankyo. Pharma Jpn 2001 1754 July 16 1-3
57. 422782 Industry - Healthcare (pharmaceuticals). Mita M Morgan Stanley Dean Witter 2001 September 11
58. 427419 Novartis R&D Day October 30, 2001 Novartis AG Company Presentation 2001 October 30
59. 430152 Sankyo aims at US sales of ¥360 bill in FY2010. Pharma Jpn 2001 1771 4
60. 430648 Sankyo planning late pII study on pitavastatin in US. Pharma Jpn 2001 1770 20
61. 434141 Effect of pitavastatin in guinea pig model of postprandial lipidemia. Aoki T, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y Int Symp on Drugs Affect Lipid Metab 2001 September 9-12 59
62. 434148 Inhibition of cholesterol synthesis by pitavastatin, an HMG-CoA RI, in HepG2 cells and a cell-free system of a rat liver: The enzyme specificity of pitavastatin action. Yamazaki H, Morikawa S, Aoki T, Suzuki H, Tamaki T, Sato H, Kitahara M, Saito Y Int Symp on Drugs Affect Lipid Metab 2001 September 9-12 59
63. 434198 NK-104 inhibits expression of VCAM-1 by endothelial cells and CD36, tissue factor and MM-9 by macrophages. Hajjar DP, Nicholson AC, Han J, Summers B, Feirt N, Gotto Jr AM Int Symp on Drugs Affect Lipid Metab 2001 September 9-12 104
64. 434236 Studies of metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase - Does glucuronidation mediate the lactonization of pitavastatin? Fujino H, Yamada L, Shimada S, Yoneda M Int Symp on Drugs Affect Lipid Metab 2001 September 9-12 120
65. 434238 Effect of biliary exretion on the pharmacokinetics of pitavastatin (NK-104) in the dogs. Kojima J, Ohshima T, Yoneda M, Sawada H, Kawagoe J Int Symp on Drugs Affect Lipid Metab 2001 September 9-12 121
66. 440183 Novartis Annual Report 2001. Novartis AG Annual Report 2002 February 14
67. 444592 SG Cowen Securities Corp: The 22nd Annual Health Care Conference - Boston - March, 11th, 2002. Novartis AG Company Presentation 2002 March 11
68. 447025 Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R Biochem Biophys Res Commun 2001 287 8 337-342
69. 447041 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Aoki T, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y Arzneimittelforschung 2001 51 3 197-203
70. 447046 Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Suzuki H, Yamazaki H, Aoki T, Kojima J, Tamaki T, Sato F, Kitahara M, Saito Y Arzneimittelforschung 2000 50 11 995-1003
71. 447047 Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H Am J Cardiol 2000 85 2 178-183
72. 447283 General pharmacological study of an anti-hyperlipidemic agent, NK-104. Yoshinaka Y, Suzuki H, Tamaki T, Sato F, Wada Y Jpn J Pharmacol Ther 2001 29 1 59-72
73. 447825 In vivo evidence that erythropoietin protects neurons from ischemic damage. Sakanaka M, Wen TC, Matsuda S, Morishita E, Nagao M, Sasaki R Proc Natl Acad Sci USA 1998 95 8 4635-4640
74. 448097 Analyst report. CDC IXIS Securities 2001 December 06
75. 451594 Sankyo announces financial results for the year ended March 31, 2002. Sankyo Co Ltd Press Release 2002 May 17
76. 453500 European Model Pharma Book. Bear Stearns & Co Inc 2002 May 27